These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12958065)

  • 1. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness.
    Seftel MD; Growe GH; Petraszko T; Benny WB; Le A; Lee CY; Spinelli JJ; Sutherland HJ; Tsang P; Hogge DE
    Blood; 2004 Jan; 103(1):333-9. PubMed ID: 12958065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
    Mishima Y; Tsuno NH; Matsuhashi M; Yoshizato T; Sato T; Ikeda T; Watanabe-Okochi N; Nagura Y; Sone S; Kurokawa M; Okazaki H
    Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
    Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
    Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
    Saris A; Pavenski K
    Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
    Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
    Front Immunol; 2018; 9():1251. PubMed ID: 29951051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial.
    Hess JR; Trachtenberg FL; Assmann SF; Triulzi DJ; Kaufman RM; Strauss RG; Granger S; Slichter SJ
    Vox Sang; 2016 Oct; 111(3):281-291. PubMed ID: 27185561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study.
    Novotny VM; van Doorn R; Witvliet MD; Claas FH; Brand A
    Blood; 1995 Apr; 85(7):1736-41. PubMed ID: 7703481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
    Panch SR; Guo L; Vassallo R
    Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet refractoriness and alloimmunization.
    Slichter SJ
    Leukemia; 1998 Sep; 12 Suppl 1():S51-3. PubMed ID: 9777897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.
    Slichter SJ; Bolgiano D; Kao KJ; Kickler TS; McFarland J; McCullough J; Woodson R
    Transfus Med Rev; 2011 Apr; 25(2):102-10. PubMed ID: 21345638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prestorage leukocyte depletion is not necessarily required for the prevention of refractoriness to platelet transfusion.
    de Wolf J; Westerterp A; Smit Sibinga C; Halie MR
    Blood; 1995 Oct; 86(8):3263-4. PubMed ID: 7579424
    [No Abstract]   [Full Text] [Related]  

  • 13. Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions.
    Brand A; Claas FH; Voogt PJ; Wasser MN; Eernisse JG
    Vox Sang; 1988; 54(3):160-6. PubMed ID: 3369136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
    Sniecinski I; O'Donnell MR; Nowicki B; Hill LR
    Blood; 1988 May; 71(5):1402-7. PubMed ID: 3282572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
    Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
    Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
    Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
    Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
    Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
    J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
    Amemiya Y
    Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Refractory effect and alloimmunization after transfusion of thrombocytes].
    Volkova RI; Agranenko VA
    Gematol Transfuziol; 1992 Feb; 37(2):16-21. PubMed ID: 1426903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.